Scott C. Brun
Independent DirectorDr. Scott C. Brun, M.D. serves as Director at Trishula Therapeutics Inc. He served as an Independent Director of Jasper Therapeutics, Inc. since June 2023 until July 16, 2026. He served as Member of Scientific Advisory Board at Systems Oncology, LLC until 2025. Dr. Brun was also a Senior Advisor to the business development team at Horizon Therapeutics plc (Nasdaq:HZNP) from January 2020 to January 2023. He is Member of Scientific Advisory Board at Nuanced Health, Inc. since January 2023. He served as an Independent Director at Forte Biosciences, Inc. since November 2022 until August 27, 2026. He serves as Independent Director at Cabaletta Bio, Inc. since June 24, 2021. He serves as Head of Gold Mast Consulting. He serves as Venture Partner at Abingworth LLP his expertise in Venture Capital, Clinical Co-Development. and was Senior Advisor at the firm. He serves as Director of Axial Therapeutics, Inc. (formerly known as Axial Biotherapeutics, Inc.) since February 2020. He serves as Director of Atsena Therapeutics, Inc. from 2025. Dr. Brun is President at Gold Mast Consulting, LL. In 1997, Dr. Brun joined Abbott Laboratories, where he held positions of increasing leadership responsibility in drug development within the R&D organization. When AbbVie launched as an independent biopharmaceutical company in 2013, Dr. Brun was named Vice President and Head of Pharmaceutical Development. He served as Divisional Vice President of Infectious Disease Development, Global Pharmaceutical Research and Development at Johnson & Johnson Surgical Vision, Inc. Dr. Brun served as Divisional Vice President of Infectious Diseases and Immunology Development at Abbott Laboratories, Limited. A variety of phase 2 and 3 programs initiated and executed during his tenure resulted in multiple therapies being introduced to the clinic, including Mavyret (leading global curative therapy for HCV infection), Venclexta (first in class BCL-2 inhibitor for hematologic malignancies), Orilissa (first in class GnRH antagonist for endometriosis) and Rinvoq (selective JAK-1 inhibitor for rheumatoid arthritis). More recently, Dr. Brun was Vice President of Scientific Affairs and Head of AbbVie Ventures, a corporate venture fund responsible for investment opportunities within the company’s current R&D therapeutic areas as well as technology platforms of interest. He has been a Member of Clinical and Scientific Advisory Board at Accelerator Life Science Partners since September 09, 2020. He has been a Director of Disarm Therapeutics Inc. since 2018. Dr. Brun received his BS degree in Biochemistry from the University of Illinois, Urbana- Champaign, between 1985-1989 and subsequently earned an MD degree from the Johns Hopkins University School of Medicine between 1989-1993. Dr. Brun is a Venture Partner at Abingworth LLP and a Senior Medical Advisor at Launch Therapeutics. He completed his residency in ophthalmology at the Massachusetts Eye and Ear Infirmary/Harvard Medical School.
Positions
- Company NameCabaletta Bio, Inc.Stock CodeCABAPositionIndependent DirectorColleagues
- SASteven A. NichtbergerCo-Founder, Chairman, CEO & President
- DJDavid J. ChangChief Medical Officer
- GKGwendolyn K. BinderPresident of Science & Technology
- MCMichael C. MiloneCo-Founder & Co-Chair of Scientific Advisory Board
- APAimee PayneCo-Founder & Co-Chair of Scientific Advisory Board
- RCRichard C. HenriquesIndependent Director
